Clinical and immunomodulatory effects of epoetin alfa in chronic anaemia of patients with systemic lupus erythematosus

Research output: Contribution to journalArticle

1 Citation (Scopus)


Systemic lupus erythematosus (SLE) is an autoimmune disorder with haematological complications. The present study investigated the clinical efficacy of epoetin alfa (50 IU/kg subcutaneously 3 times per week for 5 weeks) and its effect on complement-containing immune complex (IC) binding capacity erythrocyte complement type 1 (E-CR1) receptors in 10 female patients with lupus nephritis and concomitant anaemia (mean (± SD) haemoglobin (Hb) level 10. 3 ± 0. 9 g/dl). Treatment with epoetin alfa significantly stimulated erythropoiesis, as indicated by increases in reticulocyte count, Hb level and RBC count. This was associated with an improvement in clinical condition, as indicated by decreases in Westergreen ratio, serum creatinine level and anti-native (double-stranded) DNA antibody titre. In addition, an increase in E-CR1 receptor functional activity was observed. There was a positive correlation between E-CR1 receptor IC binding activity and reticulocyte count, suggesting that epoetin alfa increases the expression of E-CR1 receptors. Taken together, these findings suggest that epoetin alfa is effective for correction of chronic anaemia in patients with SLE and is also associated with a beneficial immunological effect.

Original languageEnglish
Pages (from-to)74-79
Number of pages6
JournalErythropoiesis: New Dimensions in the Treatment of Anaemia
Issue number3
Publication statusPublished - Jan 1 1997


ASJC Scopus subject areas

  • Hematology

Cite this